Follow Healthline   |   Healthline on TwitterTwitter   |   Healthline on FacebookFacebook
Symptom Search   |   Treatment Search   |   Doctor Search   |   Drug Search

Drug Notebook

FDA Alerts

  • Hyperkalemia (i.e., serum potassium concentrations ≥5.5 mEq/L) may occur with all potassium-sparing agents, including triamterene. More likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in geriatric or severely ill patients or those receiving prolonged therapy with large doses.
  • Uncorrected hyperkalemia may be fatal; monitor serum potassium concentrations at frequent intervals especially during initial therapy, after dosage adjustment, or in patients with concurrent illness that may affect renal function.

Media Gallery
Drug Info Tools
Search by color, shape and markings. click here
Check any 2 drugs for interactions. click here
Compare any two drugs side by side. click here
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
triamterene
(trye AM ter een)
DYRENIUM 50 SKF DYRENIUM 50 SKF | 50 mgDYRENIUM 50 SKF DYRENIUM 50 SKF   50 mg
bottle, 100 each Triamterene 50mg, Oral capsule, red, oblong-shaped, side 1:DYRENIUM 50 SKF DYRENIUM 50 SKF
DYRENIUM 100 mg DYRENIUM WPC 003 | 100 mgDYRENIUM 100 mg DYRENIUM WPC 003   100 mg
bottle, 100 each Triamterene 100mg, Oral capsule, red, oblong-shaped, side 1:DYRENIUM 100 mg DYRENIUM WPC 003
Back to Top